The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Several international trade union organizations, including the International Trade Union Confederation, Trade Union Confederation of the Americas, and the World Federation of Trade Unions, condemned the attack. Environmental NGOs, including Greenpeace and Oil Change International, have criticised the United States' oil-motivated actions in Venezuela and reiterated calls for a just transition away from fossil fuels. The Federal Council of Switzerland decided to freeze any assets held in the country by Nicolás Maduro.
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
== Contraindications and special caution == Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.
CTC has also been applied to the staining of unmelted sections of sea ice sampled during spring and summer, which were subsequently returned to the ice core holes they were collected from for in situ incubation. After recollection, metabolic activity was halted by adding a fixative into the melting sea ice. DAPI and Alcian Blue were then used to stain subsamples of the resulting melted sea ice sample, bypassing the restrictive temperature requirement. It was found that gel-like particles of EPS associated with bacteria were in situ bacterial activity hotspots. Extracellular enzyme activity has been detected down to as low as –18 °C in unmelted sea ice using a fluorescently-labeled protein substrate analogue. Relying on melted sea ice samples runs the risk of underestimating in situ activity due to the dilution of microbial populations.
Sources: en.wikipedia.org
== Role == Acetyl-CoA is a metabolic intermediate that is involved in many metabolic pathways in an organism. It is produced during the breakdown of glucose, fatty acids, and amino acids, and is used in the synthesis of many other biomolecules, including cholesterol, fatty acids, and ketone bodies. Acetyl-CoA is also a key molecule in the citric acid cycle, which is a series of chemical reactions that occur in the mitochondria of cells and is responsible for generating energy in the form of ATP. In addition, acetyl-CoA is a precursor for the biosynthesis of various acetyl-chemicals, acting as an intermediate to transfer an acetyl group during the biosynthesis of those acetyl-chemicals. Acetyl-CoA is also involved in the regulation of various cellular mechanisms by providing acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins.
A centenarian is a person who has reached the age of 100. Because life expectancies at birth worldwide are well below 100, the term is invariably associated with longevity. The United Nations estimated that there were 316,600 living centenarians worldwide in 2012, and 573,000 in 2020, almost quadruple the 2000 estimate of 151,000. As world population and life expectancy continue to increase, the number of centenarians is expected to increase substantially in the 21st century. According to the Office of National Statistics in the United Kingdom, one-third of babies born in the country in 2013 are expected to live to 100. According to a 1998 United Nations demographic survey, Japan is expected to have 272,000 centenarians by 2050; other sources suggest that the number could be closer to 1 million. The incidence of centenarians in Japan was one per 3,522 people in 2008. In Japan (as in most countries), the population of centenarians is highly skewed towards women. Japan in fiscal year 2016 had 57,525 female centenarians, while there were 8,167 males, a ratio of 7:1. The increase of centenarians was even more skewed, at 11.6:1.
SJS, like TEN and erythema multiforme, is characterized by confluent epidermal necrosis with minimal associated inflammation. The acuity is apparent from the (normal) basket weave-like pattern of the stratum corneum.
=== Neurotransmitter actions === As explained above, the only direct action of a neurotransmitter is to activate a receptor. Therefore, the effects of a neurotransmitter system depend on the connections of the neurons that use the transmitter, and the chemical properties of the receptors.
==== Enolisation ==== Enolisation of RuBP is the conversion of the keto tautomer of RuBP to an enediol(ate). Enolisation is initiated by deprotonation at C3. The enzyme base in this step has been debated, but the steric constraints observed in crystal structures have made Lys210 the most likely candidate. Specifically, the carbamate oxygen on Lys210 that is not coordinated with the Mg ion deprotonates the C3 carbon of RuBP to form a 2,3-enediolate.
Sources: en.wikipedia.org
=== 10 January === Ukrainian steel production was reduced by about 70% in 2022 as a result of the conflict. US and Ukrainian officials stated that Russian artillery fire had declined nearly 75% in some places. The UK said most of Soledar was under Russian control, whereas Wagner claimed all.
Fujirebio is a Japanese multinational in vitro diagnostics (IVD) company, founded in 1950 and headquartered in Tokyo, Japan. The company develops, manufactures, and markets IVD testing products — including reagents, instruments, and software — for clinical diagnostics and research use. Fujirebio operates offices in Asia, Europe, and the United States, and maintains a broad international distribution network, with manufacturing facilities in Japan, Europe, and the United States. The company employs more than 1,400 people globally. Fujirebio operates an open business model in which it develops novel biomarkers and diagnostic content, validates them using its own fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform, and distributes them globally through partnerships and a Contract Development and Manufacturing Organization (CDMO) model — providing development, manufacturing, and regulatory services to third-party diagnostic companies. The company’s principal areas of expertise include oncology, infectious diseases, and neurological disorders. In May 2025, Fujirebio received FDA 510(k) clearance for the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based IVD test to aid in identifying amyloid pathology associated with Alzheimer’s disease. In 2022, Fujirebio acquired ADx NeuroSciences, a Belgian biotech company specializing in neurological biomarker research, for €40 million. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc.
=== United States === In the United States it is legal to purchase poppy seeds, but all other parts of the plant are considered Schedule II controlled substances under the federal Controlled Substances Act of 1970. Unwashed poppy seeds can potentially contain lethal concentrations of morphine but only in excessively large quantities (e.g. multiple pounds of seeds). The Opium Poppy Exclusion Act of 1942 bans growing the poppy in many cases but is generally not a problem for gardeners as the plant is widely grown for the flowers, and for seeds for replanting and cooking. For much of US history poppies were a significant cash crop, and the government encouraged farmers to grow more poppies for medicinal use during wars up to World War I. It is, however, manufacture of a schedule II substance to create a drink for the opium content, and the possession of it is illegal as well.
== Practice of therapeutic drug monitoring == Automated analytical methods such as enzyme multiplied immunoassay technique or fluorescence polarization immunoassay are widely available in medical laboratories for drugs frequently measured in practice. Nowadays, most other drugs can be readily measured in blood or plasma using versatile methods such as liquid chromatography–mass spectrometry or gas chromatography–mass spectrometry, which progressively replaced high-performance liquid chromatography. Yet, TDM is not limited to the provision of precise and accurate concentration measurement results, it also involves appropriate medical interpretation, based on robust scientific knowledge. In order to guarantee the quality of this clinical interpretation, it is essential that the sample be taken under good conditions: i.e., preferably under a stable dosage, at a standardized sampling time (often at the end of a dosing interval), excluding any source of bias (sample contamination or dilution, analytical interferences) and having carefully recorded the sampling time, the last dose intake time, the current dosage and the influential patient's characteristics.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.